LG Chem said Thursday that it has signed a technology transfer agreement with PDC line Pharmaceutical for the latter’s non-small cell lung cancer anti-cancer vaccine.
|LG Science Park in Gayang-dong, Seoul.|
An anti-cancer vaccine is an immunity-based chemotherapeutic agent that induces activation of immune cells by recognizing specific cancer antigens in cells, which transmit immune signals.
Founded in April 2014, as a spin-off of the French Blood Bank, PDC line is the only company in the world developing a unique anti-cancer vaccine that uses a specific type of dendritic cell.
LG Chem concluded the agreement based on PDC's plasmacytoid dendritic cell-based anticancer vaccine, which the company believes causes a stronger cancer-specific immune response than anticancer vaccines based on conventional dendritic cells.
As PDC cell line production method mass produces cell line cultured with allogeneic cells in advance, patients can receive the injection immediately after the prescription and repeat administration as the treatment has no immune rejection reactions.
Currently, most anti-cancer vaccine development tasks use a customized method of extracting and culturing the patient's autologous cells, which requires a certain period to produce the therapeutic agent.
Under the accord, LG Chem has secured exclusive rights to develop and distribute the candidate substance locally and is eligible to expand its rights to all of Asia, including China and Japan.
PDC will receive a down payment, development option payment, and milestone payments upon achieving clinical stages, plus royalties for the development and commercialization. Also, after commercialization, the company will receive additional fees based on revenue made from LG Chem.
“The company is concentrating its R&D capabilities on developing new drugs in the field of cell-based immunotherapy, which can increase the likelihood of curing cancer patients,” said Son Jee-woong, head of LG Chem's Life Science Business Division. “We will develop innovative anti-cancer vaccines using next-generation technologies to expand treatment opportunities for cancer patients.”
PDC line Pharmaceutical CEO Eric Halioua also said, “Through this partnership, we will work closely with LG Chem to expand the company's new drug development area and provide improved treatment benefits for cancer patients worldwide.”
<© Korea Biomedical Review, All rights reserved.>